TLDR: Rarity Bioscience closes $7M funding round
Key Points:
- Rarity Bioscience closed a $7 million funding round led by Navigare Ventures
- The funding will be used to develop nucleic acid mutation detection technology and enhance operational capabilities
On June 18, 2024, molecular biotech firm Rarity Bioscience announced the successful closure of a $7 million funding round. Led by Navigare Ventures, with participation from existing shareholders and strategic investors, the funding will be used to further develop the company’s SuperRCA nucleic acid mutation detection technology for research and clinical use. The company, based in Uppsala, Sweden, plans to accelerate commercialization and market strategy, as well as enhance operational capabilities to democratize nucleic acid mutation detection.
In addition to the funding, Alex Basu from Navigare Ventures and Jaroslav Belotserkovsky from Novalis Biotech will join Rarity’s board of directors. This funding round highlights the company’s mission to advance molecular diagnostics and improve disease detection for research and clinical applications.
